Novo Nordisk faces slowing growth, competition, regulatory risks, and Wegovy pricing pressure, with DCF showing fair ...
CorMedix faces DefenCath TDAPA 2026 cuts, $300–$320m guidance, and TPN and REZZAYO risk. Find out why CRMD stock is ...
Bank of America Global Research upped its rating on Regeneron Pharmaceuticals and its price target to $860 because it has a ...
10h
Looking At The Narrative For Northrop Grumman NOC After Shifting Street Views On Growth And Returns
The fair value estimate for Northrop Grumman has been adjusted slightly to about US$665 per share from roughly US$663, with ...
Why Elecnor (BME:ENO) is on investors’ radar Elecnor (BME:ENO) has drawn fresh attention after recent share price moves, with ...
This K-Drama tells the story of an innocent man framed for horrific crimes and his fight for justice in this must-watch ...
From lab space and coffee bars to jobs and long-term returns, mid-tier life sciences hubs may be better positioned than the biggest biotech boomtowns.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback